-
William Blum, MD; Emory University Winship Cancer Institute; #DDHO2022
19:49
-
Advances in biomarker-driven therapy in AML_Eunice Wang, MD; #BeyondASCO
15:08
-
New Directions in the Treatment of Relapsed and Refractory AML_Gail Roboz, MD; #hemeupdates2022
12:35
-
What’s New in Upfront Treatment of AML?_Joseph Jurcic, MD; #hemeupdates2022
14:44
-
Hot topics in the management of AML_Eunice Wang, MD; #BeyondTheCongress
14:27
-
What’s new in upfront treatment of AML_Selina Luger, MD, FRCPC; #BeyondTheCongress
15:27
-
New directions in the treatment of relapsed and refractory AML_Courtney DiNardo, MD; #BeyondTheCongress
11:13
-
Daniel Pollyea, MD; University of Colorado School of Medicine; 5Live #ASH21
5:03
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
Alice Mims, MD; The Ohio State University Comprehensive Cancer Center; 5Live #ASH21
6:20
Key insights from the 2021 Annual Hematology meeting in Atlanta
-
AML in the Elderly- Is there a standard of care?_Martha Arellano, MD; #DDHO2021
3:49
-
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
18:13
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company